Nano Dimension LTD Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Nano Dimension provides further details on its proposed business combination with Infinite Epigenetics, emphasizing Infinite's established science, commercial operations, and AI-driven diagnostics platform.
NASDAQ
Nano Dimension Ltd. has entered into a non-binding term sheet to combine with Infinite Epigenetics, an AI-powered preventive health and diagnostics company, aiming to create a Nasdaq-listed entity focused on AI and epigenetics.
NASDAQ
CEO David Stehlin disposed of 19,841 ordinary shares of Nano Dimension Ltd. to satisfy tax obligations related to RSU vesting.
NASDAQ
Nano Dimension Ltd. reports a Form 4 filing detailing share acquisition by Director Andrew Sriubas.
NASDAQ
Nano Dimension Ltd. director Joshua Rosensweig reported the acquisition of 285,000 ordinary shares through Restricted Stock Units (RSUs) on January 1, 2026.
NASDAQ
Director Phillip Borenstein was granted 60,000 restricted stock units in Nano Dimension Ltd. as part of the company's 2015 Stock Option Plan.
NASDAQ
Nano Dimension Ltd. director Robert M. Pons was granted 260,000 restricted stock units as part of annual and special equity compensation.
NASDAQ
CEO David Stehlin reports the acquisition of 200,000 RSUs and subsequent tax-related share withholdings.